Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruboxistaurin for Vision Loss in Diabetic Macular Edema
NCT00133952Phase 3Completed
- Sponsor
- Chromaderm
- Start
- Aug 2005
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in diabetic macular edema (DME) comparing Ruboxistaurin with Placebo (2 arms). Primary endpoint: Percentage of Participants With Sustained Moderate Visual Loss at 48 months. Started Aug 2005; status: completed.
02
Drugs
ruboxistaurin
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT00133952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00133952.